4.23

3.20% -0.14

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.37

Offen:

$4.41

24-Stunden-Volumen:

9.92M

Relative Volume:

0.66

Marktkapitalisierung:

$1.89B

Einnahmen:

$285.55M

Nettoeinkommen (Verlust:

$-353.86M

KGV:

-4.4522

EPS:

-0.9501

Netto-Cashflow:

$-305.02M

1W Leistung:

-1.86%

1M Leistung:

+11.90%

6M Leistung:

+72.65%

1J Leistung:

+119.17%

1-Tages-Spanne:

$4.145

$4.45

1-Wochen-Bereich:

$4.07

$4.5399

52-Wochen-Spanne:

$1.70

$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

975

Twitter

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	4.23	1.89B	285.55M	-353.86M	-305.02M	-0.9501
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-25	Hochstufung	Citizens	Mkt Perform → Mkt Outperform
2025-07-15	Herabstufung	Goldman	Neutral → Sell
2025-05-16	Herabstufung	UBS	Buy → Neutral
2025-05-12	Herabstufung	Truist	Buy → Hold
2025-05-09	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Jul 11, 2026

Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative - Sahm

Jul 11, 2026

Jul 10, 2026

Why Is IOVA Stock Falling Today? - Stocktwits

Jul 10, 2026

Jul 09, 2026

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits

Jul 09, 2026

Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey

Jul 09, 2026

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits

Jul 09, 2026

Jul 08, 2026

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com

Jul 08, 2026

This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool

Jul 08, 2026

Jul 07, 2026

Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView

Jul 07, 2026

Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance - TradingView

Jul 02, 2026

Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028 - Stock Titan

Jul 02, 2026

IOVA Stock Price, Quote & Chart - ChartMill

Jul 02, 2026

Jun 30, 2026

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits

Jun 30, 2026

Jun 29, 2026

IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Jun 29, 2026

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen - ChartMill

Jun 29, 2026

Jun 28, 2026

Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 28, 2026

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits

Jun 28, 2026

Jun 27, 2026

Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView

Jun 27, 2026

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join - The National Law Review

Jun 27, 2026

Why Iovance Biotherapeutics (IOVA) Is Up 7.7% After Australian Conditional OK For Amtagvi Cell Therapy - Sahm

Jun 27, 2026